US Edition
News from endpoints.news
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top endpoints.news News
Alzheimer's Disease · BenningtonDeal includes $80 million upfront payment, with total potential value up to $1.04 billion plus royaltiesADEL grants exclusive worldwide rights for acetylated tau-targeting antibody 'ADEL-Y01' to SanofiADEL's proprietary platform targeting tau modification (acetylation) as a breakthrough approach for neurodegenerative diseasesSee the Story
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
62% Center coverage: 16 sources
Vaccines · United StatesThe U.S. Food and Drug Administration has no plans to put a "black box" warning on COVID-19 vaccines, Bloomberg News reported on Monday, citing the agency's top official Marty Makary.See the Story
Makary denies plans for COVID-19 black box warning
40% Right coverage: 10 sources
FDA · United States(MedPage Today) -- The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results...See the Story
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment
80% Center coverage: 10 sources
